Delivery Order SPE2DB24D2205-SPE2DB25FEHTU
- Not listed
- The Defense Logistics Agency awarded a $17,257.88 delivery order to AmerisourceBergen Drug Corp on June 9, 2025, for the supply of Enbrel 50 mg/ml syringes. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml syringes valued at $68,950.48 on September 12, 2025, with completion targeted for September 15, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999.00 ceiling and extends through December 2026. The place of...
- The Defense Logistics Agency awarded a $29,419.28 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Enbrel 50 mg/ml syringes. The contract, which carries an ultimate completion date of August 8, 2025, represents a non-set-aside, competitively awarded procurement with performance fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $9,158.68 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml syringes. The contract is a firm fixed price delivery order with an ultimate completion date of August 1, 2025, and was awarded on July 31, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was used for this competitive award. This delivery order is issued under...
- The Defense Logistics Agency awarded a $14.5K delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of ENBREL 25 mg/0.5 ml syringes. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Enbrel 50 mg/mL syringes, valued at $9,158.68 with a firm fixed price structure. The contract has an ultimate completion date of August 15, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This is a non-set-aside competitive award issued as a child delivery order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Enbrel 50 mg/mL syringes valued at $23,085.89. This is a firm fixed price delivery order with an ultimate completion date of August 27, 2025, issued with no set-aside designation, indicating competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for ENBREL 50 mg/ml syringes valued at $29,284.84. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery order will be fulfilled at the contractor's Conshohocken, Pennsylvania facility with...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Enbrel 50 mg/ml SureClick auto-injectors. This competitively awarded, non-set-aside contract carries a ceiling value of $9,476.47 under firm fixed-price terms, with an ultimate completion date of September 3, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the...
- The Defense Logistics Agency awarded a $22,930.62 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL syringes. The contract, issued on May 30, 2025, with an ultimate completion date of June 2, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor supporting federal medical procurement needs, particularly for military and...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEHTUDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Enbrel 50 mg/mL syringes with a ceiling value of $13,602.12. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The performance location is the company's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical federal vendor for military and veteran healthcare systems. The company's extensive contract portfolio with the Defense Logistics Agency demonstrates its capability to supply a comprehensive range of pharmaceutical products and medical commodities across multiple therapeutic domains. The Enbrel delivery order supports the military healthcare supply chain by providing this biologic immunosuppressant medication, which is commonly used in the treatment of rheumatoid arthritis and other inflammatory conditions. The ultimate completion date for this delivery order is September 19, 2025.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.6k | 9/18/25 |